Browsing by Author "Alizada, Said"
Now showing 1 - 20 of 26
- Results Per Page
- Sort Options
Conference Object Can the Age of the First Symptom for Neuromyelitis Optica be Used to Predict Cognitive Impairment(Sage Publications Ltd, 2024) Unal, Gozde Deniz; Alizada, Said; Kara, Irem; Simsek, Yasemin; Ozakbas, SerkanConference Object Can the age of the first symptom for neuromyelitis optica be used to predict cognitive impairment?(Sage Publications Ltd, 2024) Unal, Gozde Deniz; Alizada, Said; Kara, Irem; Simsek, Yasemin; Ozakbas, Serkan[No abstract available]Conference Object Clinical Comparison of Early and Late Onset Multiple Sclerosis at Age 35: Implications for Disease Progression and Management(Sage Publications Ltd, 2024) Kaya, Ergi; Aslan, Taha; Ozdogar, Asiye Tuba; Alizada, Said; Ozakbas, SerkanConference Object Cognitive Profiles of Relapsing Multiple Sclerosis Patients With Progression Independent of Relapse Activity Versus Non-NEDA Status(Sage Publications Ltd, 2025) Alizada, Said; Ozdogar, Asiye Tuba; Samadzade, Ulvi; Caliskan, Can; Ozakbas, SerkanConference Object Determinants of Fatigue in People With Multiple Sclerosis: An Investigative Analysis(Sage Publications Ltd, 2024) Ozdogar, Asiye Tuba; Alizada, Said; Simsek, Yasemin; Ozakbas, SerkanConference Object Determinants of Postpartum Relapse in Multiple Sclerosis: a Comprehensive Analysis of Demographic and Clinical Factors(Sage Publications Ltd, 2024) Alizada, Said; Samadzade, Ulvi; Yapici, Nurbanu; Kaya, Ergi; Ozdogar, Asiye Tuba; Ozakbas, SerkanConference Object Enhancing Disability Progression Assessment in Multiple Sclerosis: Introducing the EDSS-Plus Score(Sage Publications Ltd, 2024) Ozcelik, Sinem; Ozdogar, Asiye Tuba; Alizada, Said; Cinar, Bilge Piri; Ozakbas, SerkanConference Object Evaluating the Effectiveness of No Evidence of Disease Activity-3 in Managing Progression Independent of Relapse Activity and Relapse-Associated Worsening in Multiple Sclerosis(Sage Publications Ltd, 2024) Ozcelik, Sinem; Ozdogar, Asiye Tuba; Alizada, Said; Ozakbas, Serkan[No Abstract Available]Article Familial Multiple Sclerosis Is Associated With Accelerated Progression to Secondary Progressive Phase: A Retrospective Single-Center Cohort Study(Springer Heidelberg, 2025) Ozakbas, Serkan; Alizada, Said; Caliskan, Can; Simsek, Yasemin; Zengin, Ela SimayBackground Familial multiple sclerosis (MS), defined by the occurrence of MS in one or more relatives, is thought to represent a genetically influenced subtype of the disease. Objective To compare clinical progression, cerebrospinal fluid (CSF) parameters, and treatment responses between familial and sporadic MS patients. Methods We conducted a retrospective analysis of 1,035 patients diagnosed with MS according to the 2017 McDonald criteria (523 familial, 512 sporadic). Demographic variables, MS subtypes, expanded disability status scale (EDSS) scores, CSF oligoclonal band (OCB) status, IgG index, and treatment regimens were evaluated. Statistical tests included t tests, chi-square, and multivariable regression. Results Familial MS patients showed a higher incidence of secondary progressive MS (10.9%) compared to sporadic cases (7.0%, p = 0.030). Disease duration was significantly longer in familial MS (14.5 vs. 12.3 years, p < 0.01) though time to diagnosis did not differ. OCB positivity rates were comparable, but the IgG index was significantly elevated in familial MS (p < 0.01). Treatment responses did not differ between groups. Conclusion Familial MS is associated with more rapid disease progression and enhanced humoral immune activation, suggesting a distinct phenotype. These findings support the need for genetic and immunologic investigations to guide personalized treatment strategies.Conference Object Familial Multiple Sclerosis: Unveiling Disease Progression and Clinical Correlates(Sage Publications Ltd, 2024) Simsek, Yasemin; Alizada, Said; Caliskan, Can; Ozakbas, SerkanConference Object Five Years of Ocrelizumab in MS: Clinical Stability and Subtle Cognitive Gains(Sage Publications Ltd, 2025) Ozakbas, Serkan; Samadzade, Ulvi; Unal, Gozde Deniz; Caliskan, Can; Kara, Irem; Alizada, SaidConference Object Five-Year Real-World Outcomes of Fingolimod in Multiple Sclerosis: Long-Term Effectiveness and Treatment Continuation Patterns(Sage Publications Ltd, 2025) Ozakbas, Serkan; Alizada, Said; Samadzade, Ulvi; Caliskan, CanConference Object Impact of Chronic Pain on Cognitive Reserve in Multiple Sclerosis(Sage Publications Ltd, 2025) Ozdogar, Asiye Tuba; Kahraman, Turhan; Alizada, Said; Ozakbas, SerkanConference Object Longitudinal Impact of Fingolimod on Disease Course in Multiple Sclerosis: A Three-Year Pre- and Post-Treatment Analysis(Sage Publications Ltd, 2025) Alizada, Said; Samadzade, Ulvi; Caliskan, Can; Mammadov, Orkhan; Ozakbas, SerkanConference Object The Oligoclonal Band Dilemma: Decoding Its Role in Predicting Relapsing-Remitting Multiple Sclerosis Progression(Sage Publications Ltd, 2024) Baba, Cavid; Alizada, Said; Samadzade, Ulvi; Cevik, Sumeyye; Yapici, Nurbanu; Simsek, Yasemin; Ozakbas, SerkanConference Object Pregnancy and Disease Activity in Neuromyelitis Optica Spectrum Disorder: A Retrospective Study of Relapse Burden and Disability Progression(Sage Publications Ltd, 2025) Caliskan, Can; Simsek, Yasemin; Alizada, Said; Zengin, Ela; Ozakbas, SerkanConference Object Prevalence and Impact of Pain on Quality of Life in a Large Multiple Sclerosis Cohort: A Cross-Sectional Study(Sage Publications Ltd, 2025) Alizada, Said; Ozdogar, Asiye Tuba; Kara, Irem; Kahraman, Turhan; Ozakbas, SerkanConference Object Prevalence of Various Cancer Types Among Multiple Sclerosis Patients: Insights From a Retrospective Analysis(Sage Publications Ltd, 2024) Alizada, Said; Simsek, Yasemin; Ozakbas, SerkanConference Object The Prognostic Role of Type 2 and Type 3 Oligoclonal Bands in Multiple Sclerosis: A Five-Year Clinical Outcome Comparison(Sage Publications Ltd, 2025) Cevik, Sumeyye; Alizada, Said; Zengin, Ela; Samadzade, Ulvi; Yapici, Nurbanu; Baba, Cavid; Ozakbas, SerkanArticle Prognostic Significance of Oligoclonal Bands and Their Subtypes in Relapsing-Remitting Multiple Sclerosis(Elsevier Sci Ltd, 2025) Ozakbas, Serkan; Alizada, Said; Cevik, Sumeyye; Samadzade, Ulvi; Yapici, Nurbanu Aygunduz; Zengin, Ela Simay; Caliskan, CanObjective: To investigate the long-term prognostic significance of cerebrospinal fluid oligoclonal band (OCB) positivity and its subtypes (Type 2 and Type 3) in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: This retrospective cohort included 2324 RRMS patients diagnosed using the 2017 McDonald criteria. All patients had documented OCB status and at least 2 years of clinical follow-up; a subset had 5-year data. Outcomes included Expanded Disability Status Scale (EDSS), annualised relapse rate (ARR), and conversion to secondary progressive MS (SPMS). Subgroup analysis compared Type 2 and Type 3 OCBpositive patients. Results: OCB positivity was observed in 82.4 % of patients. At year 2, no significant differences in EDSS, ARR, or SPMS conversion were found between OCB-positive and OCB-negative groups. However, by year 5, the OCBpositive group had a significantly higher rate of conversion to SPMS (p < 0.05). Subgroup analysis showed that Type 3 OCB patients had significantly lower EDSS scores at year 2 compared to Type 2 (p < 0.05), but this difference disappeared at year 5. Conclusion: OCB positivity may be associated with a higher risk of progression to SPMS over the long term. Type 3 OCB may indicate a milder early disease course, although its protective effect diminishes over time. Incorporating OCB subtype analysis into RRMS prognosis may enhance early risk stratification.
